What the research found

This isn't a research report—it's a conference summary. PepMed 2026, the inaugural congress of the American Academy of Peptide Medicine, took place in September in Washington, DC. The event brought together physicians from multiple specialties (women's health, cardiology, sports medicine, metabolic health, regenerative medicine) to discuss peptide therapeutics. Sessions addressed clinical evidence, regulatory pathways, compounding quality, patient selection, and the gap between biological plausibility and proven treatment effects.

The conference programming deliberately positioned "responsible access"—defined as credible information, qualified clinical oversight, appropriate monitoring, and lawful care pathways—alongside clinical innovation. This framing acknowledged that wider adoption and higher evidentiary standards should advance together, rather than as competing priorities.

Why it matters for you

If you're using MyKine to track peptides alongside biomarkers and protocols, the tension highlighted at PepMed directly affects your care. Peptide use sits in a grey zone: there's genuine mechanistic rationale for many compounds, but clinical evidence lags behind enthusiasm. A clinician who takes both your experience and the evidence seriously—who listens to what you observe but doesn't overstate what one person's results prove—is rare and worth identifying.

The emphasis on specialty-specific contexts also matters. Women's health, metabolic health, and athletic performance raise different questions about dosing, monitoring, and safety. A protocol that works in one context may transfer poorly to another. The more your provider knows about peptides within your specific circumstance, the better your chances of meaningful gains and accurate interpretation of your bloodwork.

Caveats

  • This is a conference report, not primary research—no new data or effect sizes
  • The program's existence doesn't establish that peptide medicine has resolved its evidence gaps; it shows the field is acknowledging them
  • "Responsible access" is aspirational framing; actual clinical practice varies widely across providers and jurisdictions
  • No information on attendance numbers, diversity of clinical approaches represented, or whether the stated commitments translate into changed practice